Clinical Trial: The Role of GABA and Neurosteroids in Premenstrual Dysphoric Disorder

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: The Role of GABA and Neurosteroids in Premenstrual Dysphoric Disorder

Brief Summary: The purpose of the study proposed is to investigate the role of neurosteroids and GABA in the pathophysiology and treatment of premenstrual dysphoric disorder (PMDD) by 1) measuring cortical gama-aminobutyric acid levels (GABA levels) using nuclear magnetic resonance spectroscopy (MRS) during the follicular and mid-luteal phases of the menstrual cycle pre and post treatment with the selective serotonin reuptake inhibitor (SSRI) fluoxetine (Prozac®, Sarafem®), and 2) correlating cerebrospinal fluid (CSF) and plasma GABA and neurosteroid levels with cortical GABA levels at these same time points. Neurosteroids to be measured include allopregnanolone, pregnenolone, and pregnenolone sulfate. Findings from women with PMDD will be compared to those of healthy subjects.

Detailed Summary:
Sponsor: University of Pennsylvania

Current Primary Outcome: Investigating role of GABA in the pathophysiology & treatment of premenstrual dysphoric disorder by measuring cortical gama-aminobutyric acid levels using nuclear magnetic resonance spectroscopy during different phases of the menstrual cycle. [ Time Frame: 2-3 months post-treatment w/ fluoxetine. ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: University of Pennsylvania

Dates:
Date Received: May 13, 2008
Date Started: March 1998
Date Completion:
Last Updated: January 3, 2017
Last Verified: January 2017